Wondering if Teleflex is a beaten down opportunity or a value trap at today’s price? Let us walk through what the numbers are really saying about the stock. After sliding 3.8% over the last week, ...

Teleflex (TFX) has quietly become a talking point after another choppy week for medtech names, with the stock drifting lower over the past week even as the past month’s performance turned positive.

The word on The Street in general, suggests a Hold analyst consensus rating for Teleflex with a $137.20 average price target, implying a 9.67% upside from current levels. In a report released today, ...

Informing patients about bariatric surgery is a comprehensive discussion, so aim to provide the most up-to-date information about both pre- and post-surgery expectations.

Today, Coloplast is announcing changes to the company’s Executive Leadership Team (ELT). The changes relate to the company’s ...

X9 is building an ultrasound-guided device used to simplify the process of inserting a needle for cannulation.

Teleflex’s TFX Interventional Urology portfolio is well positioned for sustained growth, led by UroLift’s expanding global ...

This week's Medtech in a Minute features news about Teleflex and an update on Alcon's efforts to buy Staar Surgical amid ...

Objective overview of Teleflex’s operations, strategic acquisitions, and procedural focus in healthcare technology, contextualized using russell 1000 benchmarks.

Intuitive Surgical ISRG faces a persistent headwind in one of its historically important U.S. procedure categories, namely ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teleflex (TFX – Research Report) and Xencor (XNCR – Research Report). Claim 50% Off TipRanks ...

A Wayne-based medical technology company plans to sell three business divisions to two buyers for a combined $2.03 billion.